Basic research of immunotherapy using dendritic cells derived from induced pluripotent stem cells in healthy donors and cancer patients
Not Applicable
Recruiting
- Conditions
- Advanced or recurrent gastrointestinal cancer
- Registration Number
- JPRN-UMIN000021105
- Lead Sponsor
- Second Department of Surgery, Wakayama Medical University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active other malignancy, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable 2)Pregnant or lactating woman 3)Sever mental impairment 4)Active or uncontrolled clinically serious infection, except local infection not influencing general status 5)Judged inappropriate by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the capacity of the DCs derived from iPS cells in healthy donors and cancer patients to prime TAA-specific CTLs comparatively with the DCs derived from peripheral blood mononuclear cells (PBMCs) in the donors and the patients
- Secondary Outcome Measures
Name Time Method To investigate the morphology of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To investigate the capacity in terms of maturation and migration of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To verify the expression of tumor associated antigen in cancer cells sampled from cancer patients